Novavax gets a new CEO

Rockville-based Novavax has announced that Stanley Erck, its former executive chairman, is taking over as the company's new CEO. Prior to joining Novavax, Erck was CEO of Iomai Corporation, which went public and eventually merged with Intercell. Erck is replacing Rahul Singhvi, who served as the company's CEO for six years. Novavax didn't explain why the change was made, but a board member said the company wishes Singhvi, "nothing but the best in his future endeavors." HHS recently granted the developer a contract worth up to $179.1 million to fund research on seasonal and pandemic influenza vaccines. Release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.